Evommune (EVMN) Net Margin (2025)
Evommune's (EVMN) quarterly Net Margin came in at 124.75% in Q3 2025, up 74.4% on a QoQ basis from 487.3% in Q1 2025.
Evommune (EVMN) Net Margin (2025) Analysis & Trends
Evommune (EVMN) has 1 years of Net Margin data on file, last reported at 124.75% in Q3 2025.
- On a quarterly basis, Net Margin changed N/A year-over-year to 124.75% in Q3 2025; TTM through Mar 2026 was 1297.07%, a N/A change from a year earlier, with the FY2025 full-year figure at 1017.32%, down 5202.0% from the prior year.
- Net Margin for Q3 2025 stood at 124.75%, up from 487.3% in the prior quarter.
- Over the last five years, Net Margin for EVMN reached as high as 124.75% in Q3 2025 and fell as low as 487.3% in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 15.02% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 34.53% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 20.17% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 30.33% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Evommune | 381.48 Mn | 170.02 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -124.75% |
| Mar 31, 2025 | -487.30% |